Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma Read more about Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
Amgen Foundation and Harvard Team Up To Offer Free Online Science Education Platform Read more about Amgen Foundation and Harvard Team Up To Offer Free Online Science Education Platform
Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers Read more about Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers
Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment Read more about Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment
Amgen Announces Voting Results Of Annual Meeting Of Stockholders Read more about Amgen Announces Voting Results Of Annual Meeting Of Stockholders
FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis Read more about FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention Read more about FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease Read more about Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
Amgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference Read more about Amgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference
Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label Read more about Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
